Currently, listed companies are using Xilong Science 3HP to conduct final scientific research effect experiments. The current clinical medical research results are very good, and we are waiting for the final clinical trial results! Especially for COVID-19, HPV, HIV, etc., as the best medical intermediate, it has very good therapeutic effects! Stay tuned in 2022! Become a company with a market value of 500 billion!
1. Xilong Science Co., Ltd. (referred to as "Xilong Science", stock code: 002584), formerly known as Xilong Chemical Co., Ltd., was founded in 1983 and listed on the Shenzhen Stock Exchange in June 2011 Listed on the stock market, it was the first to enter the capital market in the domestic chemical reagent industry and quickly refreshed the development map. Since its listing, the company has transformed from a production enterprise to a production and service enterprise; from traditional marketing to Internet marketing; from endogenous operations to a combination of external mergers and acquisitions and endogenous development.
2. The company is a key high-tech enterprise under the National Torch Plan. It participates in the drafting and revision of a number of national and industry standards, focuses on the development of core high-tech products such as distillation and electrochemistry, and owns multiple professional and advanced precision testing equipment. And many well-equipped production line workshops, undertaking a number of national and provincial scientific research projects. At the same time, the company attaches great importance to the discovery and training of technical talents. The R&D team has rich experience and its R&D capabilities have continued to develop. It has participated in 35 science and technology, innovation, and technological transformation projects such as the national and provincial and ministerial Torch Plans, and has 24 patents with independent intellectual property rights, including 11 invention patents. The company has established academician workstations and postdoctoral research workstations. Through internal training and external industry-university-research cooperation, hiring external experts and academicians, and introducing overseas high-end scholars, the company has led the company's technology development in the direction of internationalization, standardization, and high-end development.
3. Business layout. Xilong Science’s current business scope covers chemical reagents, chemical raw materials, diagnostic reagents, gene sequencing services and third-party independent medical laboratories. It has more than 1,000 employees and 6 major production The base and five major logistics distribution centers are qualified for the transportation and storage of general chemicals and hazardous chemicals. It maintains long-term strategic cooperative relationships with many industry giants such as BASF, Procter & Gamble, Solvay, SKC, and AkzoNobel of the Netherlands.
4. Reagent Segment After more than 30 years of development, the company has formed four major business segments: general reagents, PCB electronic chemicals, ultra-clean and high-purity solvents, and biological reagents, supplemented by APIs, food A high-tech product chain and industrial cluster integrating additives, laboratory products and chemical raw materials, covering nearly 10,000 product categories and more than 10,000 product specifications. At the same time, the company continues to enrich its product line through self-development and external mergers and acquisitions. In 2014, the company acquired Shenzhen Huaxun and Hunan Huaxun to rapidly promote the development of electroplating solution business. The company's marketing service network covers the country and the Asia-Pacific region, with 41 marketing branches and offices. It has developed into a professional manufacturer and integrated supplier with leading domestic chemical reagent R&D capabilities, sales coverage, and comprehensive supporting scale.
5. As an important technical carrier of the concept of precision medicine, genetic testing has good market prospects and development space. It is one of the fastest growing subdivisions in the in vitro diagnostic industry in recent years. Since 2014, the company has actively developed a large-scale layout by holding New World Biotech, Yonghe Sunshine, acquiring part of the equity of Fulgent in the United States, establishing a third-party medical laboratory, signing a strategic cooperation agreement with BASF, and holding Shandong Aikewei Biotechnology Co., Ltd. In the health industry chain, the genetic testing business has gained momentum and entered the fast lane of development.